BB

Bart Bergstein

CFO Genewity

Netherlands

Overview 

Bart Bergstein is currently the CFO at Genewity in the Netherlands, where he leverages his extensive experience in venture capital, private equity, and corporate finance. With a background that includes serving as Chairman of the Board at Lead Pharma and holding various advisory roles in the biotech industry, Bart has demonstrated expertise in M&A, investor relations, and strategic corporate development.

Work Experience 

  • Chief Financial Officer

    2024 - Current

  • Chairman Of The Board Of Directors

    2020

  • Member Advisory Committee

    2018

  • Investor

    2016

  • Business Consultant

    2016

  • Investor in Super Seton BV

    2018

    SuperSeton has developed the "SupeSeton" closed-loop silicon wire that is inserted and locked together at the ends to form a smooth ring and super secure closure within seconds. The absence of the knot in the SuperSeton results in a reduction of pain and lowered risk of complications for the patients with perianal fistula. Additionally, the innovative application device ensures the ends of the novel seton can be manually pushed together in a matter of seconds, reducing surgeon’s operation time and effort, securing a safe connection.

  • Chairman of the Board of Directors

    2016 - 2024

    ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT® technology, which have the potential to generate safe and effective immunologic responses with a known mechanism of action. Synthetic long peptides are broadly applicable to multiple targets and ideally suited for monotherapy, as essential components in combination with conventional cancer treatments, and with novel immunomodulators such as Nivolumab. SLP® immunotherapies are designed to fully harness and direct the body's own defenses towards fighting the disease. In addition, ISA has begun to develop personalized SLP® immunotherapies targeting tumor-specific, mutation-derived neo-antigens.

  • Non Executive Board Member

    2020 - 2022

    Ventinova’s new ventilation technique FCV®is unique in controlling the inspiration as well as the expiration phase during artificial ventilation of a patient. This is established by generating a continuous flow into the patient’s lungs followed by a continuous (negative) flow, sucking gasses out of the patient’s lungs. The continuous flow either into the lungs or out of the lungs, without ventilation pauses, results in linear increases and decreases in intratracheal pressures.

  • Non Executive Board Member

    2016 - 2022

    Based in Cologne (Germany), Cevec tackles with its human cell-based expression systems (CAP-GT and CAP-Go) two big challenges in Biotech manufacturing – industrial scale production of viral vectors and complex glycoproteins. CAP-GT is a platform to produce viral vectors, such as lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV). These viral vectors are used to carry genetic information to the target cells in the patient’s body in gene therapy. Cevec’s production of viral vectors has two key advantages – scalability and safety. Still, one of the biggest bottlenecks in gene therapy is the ability to produce reliable and safe vectors on an industrial scale to allow the commercial production of gene therapy products. In Oktober 2022 CEVEC was acquired by Cyteva, a subsidiary of Danaher Corp.

  • Vice Chairman

    2000 - 2022

    Mibiton Foundation provides loans for early stage life sciences companies to finance their CAPEX in equipment and facilities.

Articles About Bart

Relevant Websites